FDA Grants Accelerated Approval for KRESLADI to Treat Pediatric LAD-I
Rocket Pharmaceuticals announced that the FDA granted accelerated approval for KRESLADI (marnetegragene autotemcel), an autologous hematopoietic stem cell–based gene therapy for pediatric patients with severe LAD-I due to ITGB2 variants who lack an HLA-matched donor. Approval is based on increased neutrophil CD18/CD11a expression and will rely on longer-term follow-up data and a post‑marketing registry to confirm benefit. The FDA also awarded Rocket a Rare Pediatric Disease Priority Review Voucher, which the company plans to monetize. LAD-I is ultra-rare and causes recurrent life-threatening infections; safety concerns include infections during conditioning, veno-occlusive disease, engraftment failure, potential insertional oncogenesis, hypersensitivity, anti-retroviral interactions, and possible HIV test false positives, necessitating long-term monitoring. A conference call is planned for March 27, 2026.
- Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Business Wire
- FDA approves Rocket gene therapy for rare immune disorder statnews.com
- Rocket Pharmaceuticals Wins FDA Accelerated Approval for KRESLADI Gene Therapy in Severe LAD-I Kids Yahoo Finance
- Rocket Pharma shares fall despite FDA nod for childhood disorder treatment Reuters
- FDA approves gene therapy for severe leukocyte adhesion deficiency-I, a rare immune disorder uclahealth.org
Reading Insights
0
4
9 min
vs 11 min read
94%
2,013 → 117 words
Want the full story? Read the original article
Read on Business Wire